JP2009524428A - スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質 - Google Patents

スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質 Download PDF

Info

Publication number
JP2009524428A
JP2009524428A JP2008552351A JP2008552351A JP2009524428A JP 2009524428 A JP2009524428 A JP 2009524428A JP 2008552351 A JP2008552351 A JP 2008552351A JP 2008552351 A JP2008552351 A JP 2008552351A JP 2009524428 A JP2009524428 A JP 2009524428A
Authority
JP
Japan
Prior art keywords
seq
mab
amino acids
region
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008552351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524428A5 (https=
Inventor
ブラウン，マーサ・ジエイ
アンダーソン，アンナリーザ・エス
コープ，レスリー・デイー
ヤンセン，カトリーン・ウテ
マクニーリー，テツシー
ハーベイ，バレット
デユール，エルベルハルト
アーンスト，ロビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2009524428A publication Critical patent/JP2009524428A/ja
Publication of JP2009524428A5 publication Critical patent/JP2009524428A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008552351A 2006-01-27 2007-01-23 スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質 Withdrawn JP2009524428A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76302306P 2006-01-27 2006-01-27
PCT/US2007/001687 WO2007089470A2 (en) 2006-01-27 2007-01-23 Antigen-binding proteins targeting s. aureus orf0657n

Publications (2)

Publication Number Publication Date
JP2009524428A true JP2009524428A (ja) 2009-07-02
JP2009524428A5 JP2009524428A5 (https=) 2010-03-11

Family

ID=38327867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552351A Withdrawn JP2009524428A (ja) 2006-01-27 2007-01-23 スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質

Country Status (7)

Country Link
US (1) US20110091480A1 (https=)
EP (1) EP1982185A4 (https=)
JP (1) JP2009524428A (https=)
CN (1) CN101375161A (https=)
AU (1) AU2007210170A1 (https=)
CA (1) CA2637152A1 (https=)
WO (1) WO2007089470A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
WO2022042673A1 (zh) * 2020-08-28 2022-03-03 江苏恒瑞医药股份有限公司 用于降低异源多肽末端异质性的信号肽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
PT1377314E (pt) * 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
ATE457737T1 (de) * 2003-07-24 2010-03-15 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
CN1980692A (zh) * 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
AU2006206577B2 (en) * 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
EP2117574A4 (en) * 2007-01-24 2010-06-16 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS EPIDERMIDIS
EP2126070A4 (en) * 2007-03-19 2010-03-31 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS EPIDERMIDIS
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.

Also Published As

Publication number Publication date
WO2007089470A3 (en) 2008-01-24
EP1982185A2 (en) 2008-10-22
US20110091480A1 (en) 2011-04-21
WO2007089470A9 (en) 2007-11-01
WO2007089470A2 (en) 2007-08-09
CA2637152A1 (en) 2007-08-09
CN101375161A (zh) 2009-02-25
EP1982185A4 (en) 2010-04-28
AU2007210170A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CN101679516B (zh) 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
JP2009524428A (ja) スタヒロコッカス・アウレウスｏｒｆ０６５７ｎを標的とする抗原結合タンパク質
US9914767B2 (en) Cross-reactive Staphylococcus aureus antibody
KR102531577B1 (ko) Pcsk9 항체, 및 약제학적 조성물 및 이의 용도
JP7610515B2 (ja) ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
JP2024522670A (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
CN113416249B (zh) 针对破伤风毒素的组合物
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
RU2815280C1 (ru) Антитело против столбнячного токсина и его применение
US20240174736A1 (en) Antigen-binding protein targeting pneumolysin and use thereof
TW202506731A (zh) 治療多重抗藥性細菌感染之方法
OA21922A (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof.
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
KR20220013854A (ko) 탄저균 보호항원에 특이적인 인간화 항체 및 이의 제조방법
TW202136308A (zh) 抗ｃｓｆ１ｒ分子及其用途
HK1243095B (zh) 一种抗白介素17a 的抗体、其制备方法和应用
HK1243095A (en) An anti-il-17a antibody, the preparation method and application thereof
HK1243095A1 (en) An anti-il-17a antibody, the preparation method and application thereof
NZ618266B2 (en) Anti-pseudomonas psl binding molecules and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111208